Development of oral extended release formulations of 6-hydroxybuspirone

Biopharmaceutics and Drug Disposition

Volumn 33, Issue 9, 2012, Pages 522-535

  Nicholson, Sarah J ^a   Timmins, Peter ^a   Dockens, Randy C ^a   Connor, Alyson ^b   Croop, Robert ^a   Ferrie, Peter ^a   Zeng, Jianing ^a   Dennis, Andrew B ^a   Wilding, Ian ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b Quotient Clinical   (United Kingdom)

Author keywords

6 hydroxybuspirone; dissolution; extended release; pharmacokinetics; scintigraphy

Indexed keywords

6 HYDROXYBUSPIRONE; BUSPIRONE; CITRIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; PLACEBO; SAMARIUM 153; UNCLASSIFIED DRUG;

ARTICLE; ASTHENIA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG RELEASE; DRUG SOLUBILITY; GAMMA SCINTIGRAPHY; HUMAN; MATRIX TABLET; NAUSEA; SOMNOLENCE; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BUSPIRONE; CITRIC ACID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; METHYLCELLULOSE; MIDDLE AGED; TABLETS; YOUNG ADULT;

EID: 84871005517     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1819     Document Type: Article

References (39)

1. 13C-buspirone HCl after intravenous and oral dosing in man. Clin Pharmacol Ther 1985; 37: 210.
2. Gammans RE, Mayol RF, LaBudde JA,. Metabolism and disposition of buspirone. Am J Med 1986; 80 (Suppl B): 41-51.
3. Jaloo HK, Mayol RF, LaBudde JA, Blair IA,. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 1989; 17: 634-640.
4. Dockens RC, Salazar DE, Fulmor E, Wehling M, Arnold ME, Croop R,. Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J Clin Pharmacol 2006; 46: 1308-1312.
5. Caccia S, Conti J, Vignao G, Garattini S,. 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology 1986; 33: 46-51.
6. Dockens RC, Tran AQ, Zeng J, Croop R,. Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans. Biopharm Drug Dispos 2007; 28: 393-402.
7. Gibaldi M, Perrier D,. Pharmacokinetics (2nd edn). Marcel Dekker, Inc.: New York, 1982; 409-417.
8. Riegelman S, Collier P,. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980; 8: 509-534.
9. Wagner JG,. Pharmacokinetic absorption plots from oral data alone or oral/intravenous data and an exact Loo-Riegelman equation. J Pharm Sci 1983; 72: 838-842.
10. Bristol-Myers Squibb Company. BuSpar (buspirone HCl) tablets. In Physicians' Desk Reference (53rd edn). Thomson PDR: Montvale, NJ, 1999; 823-825.
11. Melia CD,. Hydrophilic matrix sustained release systems based on polysaccharide carriers. Crit Rev Ther Drug Carrier Syst 1991; 8: 395-421.
12. Alderman DA,. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Tech Prod Manuf 1984; 5: 1-9.
13. Colombo P, Bettini R, Snati P, Peppas NA,. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. Pharm Sci Technol Today 2000; 3: 198-204.
14. Baveja SK, Rao KVR, Devi KP,. Zero-order release hydrophilic matrix tablets of β-adrenergic blockers. Int J Pharm 1987; 39: 39-45.
15. Timmins P, Delargy AM, Howard JR,. Optimization and characterization of a pH-independent extended release hydrophilic matrix tablet. Pharm Dev Tech 1996; 2: 25-31.
16. Takka S, Rajbhandari S, Sakr A,. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm 2001; 52: 75-82.
17. Huang Y, Tsai Y, Lee S, Chang J, Wu P,. Optimization of pH-independent release of nicardipine hydrochloride extended release matrix tablets using surface response methodology. Int J Pharm 2005; 289: 87-95.
18. Gutsche S, Krause M, Kranz H,. Strategies to overcome pH-dependent solubility of weakly basic drugs by using different types of alginates. Drug Dev Ind Pharm 2008; 34: 1277-1284.
19. Gabr KE,. Effect of organic acids on the release patterns of weakly basic drugs from inert sustained release matrix tablets. Eur J Pharm Biopharm 1992; 38: 199-202.
20. Espinoza R, Hong E, Robles LV,. Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets. Int J Pharm 2000; 201: 165-173.
21. Rogelio E, Enrique H, Leopolodo V,. Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets. Int J Pharm 2000; 201: 165-173.
22. Streubel A, Siepmann J, Dashevsky A, Bodmeier R,. pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets. J Control Rel 2000; 67: 101-110.
23. Nie S, Pan W, Li X, Wu X,. The effect of citric acid added to hydroxypropyl methyl cellulose (HPMC) matrix tablets on the release profile of vinpocetine. Drug Dev Ind Pharm 2004; 30: 627-635.
24. Kranz H, Guthmann C, Wagner T, Lipp R, Reinhard J,. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug. Eur J Pharm Sci 2005; 26: 47-53.
25. Varma MS, Kaushal AM, Garg S,. Influence of micro-environmental pH on the gel layer behaviour and release of a basic drug from various hydrophilic matrices. J Control Rel 2005; 103: 499-510.
26. Siepe S, Lueckel B, Kramer A, Ries A, Gurny R,. Strategies for the design of hydrophilic matrix tablets with controlled microenvironmental pH. Int J Pharm 2006; 316: 14-20.
27. Tatarvarti AS, Hoag SW,. Microenvironmental pH modulation based release enhancement of weakly basic drug from hydrophilic matrices. J Pharm Sci 2006; 95: 1459-1468.
28. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA,. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25-35.
29. Peppas NA,. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985; 60: 110-111.
30. Ritger PL, Peppas NA,. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Rel 1987; 5: 23-36.
31. Ritger PL, Peppas NA,. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J Control Rel 1987; 5: 37-42.
32. Harland RS, Gazzaniga A, Sangalli ME, Colombo P, Peppas NA,. Drug/polymer matrix swelling and dissolution. Pharm Res 1988; 5: 488-494.
33. Siepmann J, Peppas NA,. Modelling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001; 48: 139-157.
34. 2-adrenoreceptors in the rat brain. Eur J Pharmacol 1983; 180: 183-186.
35. 2-Adrenoreceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. Eur J Pharmacol 1988; 155: 129-137.
36. Amano M, Goto A, Sakai A, et al,. Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats. Jpn J Pharmacol 1993; 61: 311-317.
37. Cao BJ, Rodgers RJ,. Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 1997; 36: 1089-1097.
38. Martin P,. 1-(2-Pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonists in the learned helplessness paradigm in rats. Psychopharmacology 1991; 1104: 275-278.
39. Davis SS, Hardy JG, Fara JW,. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 886-892.